---
schema_version: "secwatch.filing_event.v1"
accession: "0001398733-25-000022"
form_type: "8-K"
ticker: "AQST"
cik: "0001398733"
company_name: "Aquestive Therapeutics, Inc."
filed_at: "2025-10-08T23:59:59+00:00"
generated_at: "2026-05-17T04:18:14.899426+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Aquestive receives two new US patents for Anaphylm, extending protection to 2037

## Summary
- USPTO issued U.S. patent nos. 12,427,121 and 12,443,850 covering epinephrine prodrug compositions for sublingual film delivery.
- Patents expire May 4, 2037, subject to extensions; protect proprietary composition enabling oral film delivery.
- Anaphylm (dibutepinephrine) sublingual film, if FDA approved, would be first oral rescue treatment for severe allergic reactions.
- PDUFA target action date for Anaphylm is January 31, 2026.

## SEC filing metadata
- accession: 0001398733-25-000022
- form_type: 8-K
- ticker: AQST
- cik: 0001398733
- company_name: Aquestive Therapeutics, Inc.
- filed_at: 2025-10-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1398733/000139873325000022/0001398733-25-000022-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1398733/000139873325000022/aqst-20251008.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001398733-25-000022
- JSON: https://secwatch.observer/filing/0001398733-25-000022.json
- Plain text: https://secwatch.observer/filing/0001398733-25-000022.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.